MedTrace Logo

Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

NCT05033145 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2022-08-12

No results posted yet for this study

Summary

Phase III, single-center with co-participating units, randomized, double-blind, parallel, placebo-controlled clinical study

Conditions

Interventions

DRUG

AZVUDINE

AZVUDINE 5 tablets QD + standard treatment, for up to 14 days

DRUG

AZVUDINE placebo

5 tablets QD + standard treatment, for up to 14 days

Sponsors & Collaborators

  • GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil

    collaborator UNKNOWN

  • Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute

    collaborator UNKNOWN

  • HRH Pharmaceuticals Limited

    lead OTHER

Principal Investigators

  • Sheila P Figueiredo, Nurse,MSc · Galzu Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2022-07-27
Completion
2022-07-27

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05033145 on ClinicalTrials.gov